Buy
Sell
Share Name Share Symbol Market Type Share ISIN Share Description
Amryt Pharma Plc LSE:AMYT London Ordinary Share GB00BKLTQ412 ORD 6P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.00 0.0% 205.00 202.00 208.00 - 0.00 00:00:00
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Pharmaceuticals & Biotechnology 49.2 -56.5 -72.8 - 334

Amryt Pharma Share Discussion Threads

Showing 5001 to 5014 of 6475 messages
Chat Pages: Latest  211  210  209  208  207  206  205  204  203  202  201  200  Older
DateSubjectAuthorDiscuss
14/9/2019
11:33
Some (or someone) have (has) been loading up in a big way on Thursday. There were 9 big trades on Thursday where reporting was delayed that were only reported yesterday after the market closed!! From 40k all the way up to 175k shares (£44.8k up to £199.62k). Going by the prices and times the trades were completed it looks like they are a mixture of buys and sells, but going by the share price rises on Thursday and yesterday I'm pretty certain the buys outnumber the sells. Many thanks, Bermudashorts, for posting that link to the youtube video of Cathal Friel's very positive verdict on the Aegerion acquisition/RTO. He was rather fulsome in his praise for Joe Wiley and Rory Nealon on negotiating the deal. He was obviously very impressed with the way they have turned AMYT from a company whose share price was very dependent on the success, or otherwise, on a single product, AP101 into a broad based biopharma with sales of over US$130m pa whose share price wont collapse if AP101 fails the Phase III trial. I wonder if Friel was topping up on Thursday? It wouldn't surprise me. PS. I remember Amicus's share price DIDN'T collapse when Zorblisa (Socioderm's treatment for EB that was acquired by Amicus in an extremely generous deal for Socioderm shareholders) was ditched by Amicus when it was deemed to to be a failure at the interim stage of it's Phase III trial. In fact the Amicus share price hardly moved. Perhaps that was because investors felt the Amicus deal had been far too generous for Socioderm shareholders. Hopefully something similar could be the case for the AMYT share price if AP101 fails it's Phase III trial. Of course the deal for old AMYT shareholders (pre the completion of the Aegerion deal) is nowhere near as generous as that offered by Amicus to Socioderm shareholders.
papillon
13/9/2019
17:01
Mdalos, why "chance your arm", sell up and move on. You have never liked this stock, why hang about, your in the black so sell and forget about all your amryt worries.
digadee
13/9/2019
16:27
Cheers Pap I wouldn't split hairs on a difference of 4,000,000 shares ! Lol its all pie in the sky until it happens ;) Enjoy the weather and weekend :)
richpassi
13/9/2019
15:25
Cathal Friel still has around 4,116,224 shares (via his Raglan Road vehicle) in AMYT (after taking into a/c the 1 for 6 consolidation. From the AMYT web site). He has hung onto them. At the moment they are worth around £5m to him. He'll also have 4,116,224 CVR's which could be worth up to another circa £5m to him in future IF all the milestones for AP101 are achieved. Not to be sniffed at, even for someone as rich as Cathal Friel.
papillon
13/9/2019
15:09
ali47fish - this morning I believe
bermudashorts
13/9/2019
15:00
Cathal says Nasdaq plan for November
alphabravo321
13/9/2019
14:55
when is this dated bermuda please no date with the video?
ali47fish
13/9/2019
14:14
Not sure whether this has already been posted but Cathal Friel gives his views on the Aegerion deal in the Proactive interview below:- Https://www.youtube.com/watch?v=ZqelBgsW39I
bermudashorts
13/9/2019
12:46
richpassi. Re my reply to you yesterday (post 4835). I made a very silly arithmetical error in the post. I stated that the maximum value of the CVR's (if AP101 passed all it's milestones) was £1.60 when it fact the RNS dated 27th August states CATEGORICALLY that the maximum pay out is US$1.48 (equivalent to £1.22 with an exchange rate of US$1 = £1.21) If one divides the maximum amount available to the CVR holders, US85m, by US$1.48 one gets the number of CVR's in existence by the cut off date of 20th September. That gives the number of CVR's as 57.432m NOT the 53.149m I have used in my post 4835. Apologies, richpassi, for my mistakes in post 4835. Hope you agree with my corrected figures. ATB
papillon
13/9/2019
11:06
Looks like you can sell above the mid price today, which is unusual for AMYT. Indicates demand for the shares?
papillon
13/9/2019
10:55
ali47fish. There is, as alphabravo states, a US$60m share placing @ 148p per share on the 24th September. If you buy AMYT shares before the cut off date of 20th September and keep them until after 20th September, as dim2602 states, you will be entitled to the CVR's. Whether the AMYT share price will drop after the 20th September, as dim2602 states, is open to question. That would normally be the case, but will it happen in this case bearing in mind that there is a £1.48 share placing just 4 days after and a fund manager like Mark Taub (see my post yesterday containing a link to his article) believes AMYT will be vastly undervalued compared with it's peer group on Nasdaq (AMYT intends to list on Nasdaq within 90 days of the Aegerion acquisition/RTO). Mark Taub was valuing AMYT (after it acquires Aegerion following the completion of the the RTO) almost solely on the circa US$136m sales revenue of the new AMYT, so how much value is being ascribed by investors to the CVR's (which could end up worthless) who can tell? Personally I believe dim2602 is correct and we could see a small, temporary, pull back in the share price after the 20th September, but it's by no means certain.
papillon
13/9/2019
08:56
Isn't there a 60 million capital raise on Sept 24th?
chica1
13/9/2019
08:06
If you buy AMYT shares before 20th Sept and keep them until after 20th Sept you will be on the register to receive the CVRs. Its much the same as a holding a share that goes ex-dividend on a certain day. You can buy this share the day before the XD date and sell it the day after and still receive the dividend. But its not necessarily free money because the market should assume that the current AMYT share price already includes the value of the CVR's. After 20th September this element is removed from the AMYT share, so the AMYT share price should fall in value. But this fall in value should be compensated by the fact that you would hold this value through your separate ownership of the CVR. My view is that the market probably doesn't know what value to apply to the CVR as its potential payout is subject to so many outcomes. I think the AMYT share price will fall only around 5p - 10p to reflect the ex CVR status and then quickly recover.
dlm2602
13/9/2019
07:05
Buys showing as sells
alphabravo321
Chat Pages: Latest  211  210  209  208  207  206  205  204  203  202  201  200  Older
ADVFN Advertorial
Your Recent History
LSE
AMYT
Amryt Phar..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20210308 07:23:28